Physician profile
John Vani
NPI 1083727077
$4,431.75
in general payments reported to CMS, 2019-2025
21 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $16.09 · 2021: $1,224 · 2022: $102 · 2023: $620 · 2024: $259 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,522 · Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,521.54 |
| Food and Beverage | $1,155.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $1,500.57 | 2023-2025 | |
| Titan Surgical Group, LLC | $1,200.00 | 2021 | |
| Smith+Nephew, INC. | $481.41 | 2019-2023 | Real Intelligence, Journey II |
| Arthrex, INC. | $268.20 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.66 | 2023-2025 | |
| Onkos Surgical, INC. | $117.70 | 2024 | Eleos Limb Salvage System |
| Depuy Synthes Sales INC. | $103.74 | 2020-2025 | Orthovisc, Monovisc, Peak |
| Kiniksa Pharmaceuticals, LTD. | $85.87 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $75.83 | 2023 | Verquvo |
| Zimmer Biomet Holdings, INC. | $73.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.71 | 2023 | Xarelto |
| United Therapeutics Corporation | $63.03 | 2023 | Orenitram |
| Abbvie INC. | $52.16 | 2023 | Botox |
| Kiniksa Pharmaceuticals International, Plc | $43.25 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $34.04 | 2023 | Brilinta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $26.57 | 2019 | |
| Bioventus LLC | $23.91 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.47 | 2023 | Lifevest |
| Conmed Corporation | $14.61 | 2024 | Visiclear |
| Esperion Therapeutics, INC. | $14.01 | 2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.